Faropenem

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Faropenem
DrugBank Accession Number
DB12190
Background

Faropenem has been used in trials studying the treatment of Tuberculosis, Pulmonary Tuberculosis, and Community Acquired Pneumonia.

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 285.316
Monoisotopic: 285.067093285
Chemical Formula
C12H15NO5S
Synonyms
  • Faropenem

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
ADihydropteroate synthase
inhibitor
Escherichia coli (strain K12)
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Ingredients
IngredientUNIICASInChI Key
Faropenem Sodium7O46G914RQ122547-49-3ICSAXRANXQSPQP-VUKDEKJYSA-M

Categories

ATC Codes
J01DI03 — Faropenem
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acids and derivatives
Alternative Parents
Thiazolecarboxylic acids and derivatives / Penems / Vinylogous thioesters / Thiazolines / Tetrahydrofurans / Tertiary carboxylic acid amides / Azetidines / Thioenol ethers / Secondary alcohols / Azacyclic compounds
show 10 more
Substituents
Alcohol / Aliphatic heteropolycyclic compound / Alpha-amino acid or derivatives / Azacycle / Azetidine / Beta-lactam / Carbonyl group / Carboxamide group / Carboxylic acid / Dialkyl ether
show 22 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
faropenem (CHEBI:51257)
Affected organisms
Not Available

Chemical Identifiers

UNII
F52Y83BGH3
CAS number
106560-14-9
InChI Key
HGGAKXAHAYOLDJ-FHZUQPTBSA-N
InChI
InChI=1S/C12H15NO5S/c1-5(14)7-10(15)13-8(12(16)17)9(19-11(7)13)6-3-2-4-18-6/h5-7,11,14H,2-4H2,1H3,(H,16,17)/t5-,6-,7+,11-/m1/s1
IUPAC Name
(5R,6S)-6-[(1R)-1-hydroxyethyl]-7-oxo-3-[(2R)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
SMILES
[H][C@]12SC([C@H]3CCCO3)=C(N1C(=O)[C@@H]2[C@@H](C)O)C(O)=O

References

General References
Not Available
Human Metabolome Database
HMDB0041892
PubChem Compound
65894
PubChem Substance
347828475
ChemSpider
59303
ChEBI
51257
ChEMBL
CHEMBL556262
ZINC
ZINC000003959242
PDBe Ligand
FPM
Wikipedia
Faropenem
PDB Entries
3bff / 4hky

Clinical Trials

Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package
PhaseStatusPurposeConditionsCountStart DateWhy Stopped100+ additional columns
3Unknown StatusTreatmentCommunity Acquired Pneumonia (CAP)1somestatusstop reasonjust information to hide
2CompletedTreatmentCommunity Acquired Pneumonia (CAP)1somestatusstop reasonjust information to hide
2CompletedTreatmentPulmonary Tuberculosis (TB)2somestatusstop reasonjust information to hide
1CompletedTreatmentTuberculosis (TB)1somestatusstop reasonjust information to hide

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility14.7 mg/mLALOGPS
logP0.24ALOGPS
logP-0.75Chemaxon
logS-1.3ALOGPS
pKa (Strongest Acidic)3.97Chemaxon
pKa (Strongest Basic)-2.8Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area87.07 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity69.26 m3·mol-1Chemaxon
Polarizability28.16 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSsplash10-0006-9030000000-71dce16fcdf8d65d622c
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0090000000-2e62936e0d244db951e9
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-001i-0390000000-24a73c8c0d0001c0d158
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-0gbi-1190000000-ee802ec76572aeed016b
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0frx-0950000000-5fba62b9f195d438a810
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-0frb-2940000000-ca25e73482070ff51af2
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-00ke-6950000000-3af6a60d284ed112bf91
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-171.3602426
predicted
DarkChem Lite v0.1.0
[M-H]-172.1363426
predicted
DarkChem Lite v0.1.0
[M-H]-171.86546
predicted
DeepCCS 1.0 (2019)
[M+H]+170.3005426
predicted
DarkChem Lite v0.1.0
[M+H]+173.9254426
predicted
DarkChem Lite v0.1.0
[M+H]+174.22346
predicted
DeepCCS 1.0 (2019)
[M+Na]+170.6615426
predicted
DarkChem Lite v0.1.0
[M+Na]+171.9929426
predicted
DarkChem Lite v0.1.0
[M+Na]+181.3822
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Escherichia coli (strain K12)
Pharmacological action
Yes
Actions
Inhibitor
General Function
Catalyzes the condensation of para-aminobenzoate (pABA) with 6-hydroxymethyl-7,8-dihydropterin diphosphate (DHPt-PP) to form 7,8-dihydropteroate (H2Pte), the immediate precursor of folate derivatives.
Specific Function
dihydropteroate synthase activity
Gene Name
folP
Uniprot ID
P0AC13
Uniprot Name
Dihydropteroate synthase
Molecular Weight
30614.855 Da
References
  1. Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]

Drug created at October 20, 2016 21:34 / Updated at August 27, 2024 19:15